|
|
||
|---|---|---|
| UniProt ID |
Q9BYF1 |
|
| Entry Name |
ACE2_HUMAN |
|
| Protein Name |
Angiotensin-converting enzyme 2 |
|
| Primary Gene Name |
ACE2 |
|
| Organism |
Homo sapiens (Human) |
|
| Molecular Function |
Hydrolase |
|
| Membrane Location |
Secreted |
|
|
|
|---|
| Substrate Name | Angiotensin-converting enzyme 2 (ACE2) | |
| Cell Type | ||
| Substrate Description | ||
| Substrate Function Category | disease | |
| Substrate Function Subtype | Disease: infection (HIV) | |
| Sheddase | ADAM17 | |
| Shedding-related Disease | infection (HIV) | |
| Short Summary of Papers | ACE2 undergo proteolytic shedding by ADAM17, and the shed soluble form ACE2 has been shown to block binding of the SARS-CoV spike protein to its receptor | |
| Cleavage Information | NONE | |
| PMID | 17150042 |
| Substrate Name | Angiotensin-converting enzyme 2 (ACE2) | |
| Cell Type | ||
| Substrate Description | converts angiotensin to angiotensin | |
| Substrate Function Category | enzyme | |
| Substrate Function Subtype | enzyme (carboxypeptidase) | |
| Sheddase | ADAM17 | |
| Shedding-related Disease | carboxypeptidase | |
| Short Summary of Papers | infection of SARS virus (SARS-CoV) could modulate ADAM17 shedding on ACE2, facilitate viral entry | |
| Cleavage Information | NONE | |
| PMID | 15983030 18490652 |
|
|
|---|
|
|
||
|---|---|---|
|
|
Start | End |
|
|
18 | 740 |
|
|
741 | 761 |
|
|
||||||||
|---|---|---|---|---|---|---|---|---|
| Database | CutSeq | Mapped Position | Protease | Type | Evidence | PMID | ||
| PMAP | No_information | ADAM17 peptidase | This entry is based on an experiment | Gel electrophoresis | 15983030 | |||
|
|
|||
|---|---|---|---|
| Secretome Database | Cell Type or Body Fluid | PubMed Reference | |
| Sys-BodyFluid | Urine | 16948836 | |
| Sys-BodyFluid | Amniotic fluid | 17495049 | |
| Sys-BodyFluid | Seminal Fluid | 16709260 | |
| HCSD | cancer(23 cancer cell lines) | 20124221 | |
| HCSD | cancer(colorectal cancer | 24418523 | |
| HCSD | cancer(ovarian cancer) | 23805888 | |